1. Home
  2. NAKA vs PYXS Comparison

NAKA vs PYXS Comparison

Compare NAKA & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kindly MD Inc.

NAKA

Kindly MD Inc.

N/A

Current Price

$8.93

Market Cap

152.1M

Sector

N/A

ML Signal

N/A

Logo Pyxis Oncology Inc.

PYXS

Pyxis Oncology Inc.

HOLD

Current Price

$1.99

Market Cap

141.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NAKA
PYXS
Founded
2019
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
152.1M
141.3M
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
NAKA
PYXS
Price
$8.93
$1.99
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
10
Target Price
★ $13.33
$8.67
AVG Volume (30 Days)
199.5K
★ 1.1M
Earning Date
11-18-2026
11-02-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 61.19
3.03
EPS
N/A
★ N/A
Revenue
N/A
★ $13,858,000.00
Revenue This Year
$3,833.87
N/A
Revenue Next Year
N/A
$14,188.99
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.15
$1.03
52 Week High
$10.53
$5.55

Technical Indicators

Market Signals
Indicator
NAKA
PYXS
Relative Strength Index (RSI) 52.98 28.37
Support Level $0.22 $1.90
Resistance Level $10.27 $2.17
Average True Range (ATR) 0.70 0.18
MACD -0.15 -0.13
Stochastic Oscillator 21.77 4.10

Price Performance

Historical Comparison
NAKA
PYXS

About NAKA Kindly MD Inc.

Nakamoto Inc is a Bitcoin company building a world-wide portfolio of Bitcoin-native companies to provide commercial and financial infrastructure for the next generation of capital markets. The firm has two principal business segments: Bitcoin Operations, which houses its Bitcoin treasury and is utilized to support investments in other Bitcoin-related companies; Healthcare Operations, which provides a patient-focused healthcare experience that provides patients personalized solutions in order to reduce opioid use and improve health outcomes. The company generates the majority of its revenue from the Healthcare Operations.

About PYXS Pyxis Oncology Inc.

Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.

Share on Social Networks: